Artículo
Single vs. combination immunotherapeutic strategies for glioma
Chandran, Mayuri; Candolfi, Marianela
; Shah, Diana; Mineharu, Yohei; Yadav, Viveka Nand; Koschmann, Carl; Asad, Antonela Sofía
; Lowenstein, Pedro R.; Castro, Maria Gabriela
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
Fecha de publicación:
05/2017
Editorial:
Informa Healthcare
Revista:
Expert Opinion on Biological Therapy
ISSN:
1471-2598
e-ISSN:
1744-7682
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Introduction: Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). Precision immunotherapies or combinations of immunotherapies that target unique tumor-specific features may substantially improve upon existing treatments. Areas covered: Clinical trials of single immunotherapies have shown therapeutic potential in high-grade glioma patients, and emerging preclinical studies indicate that combinations of immunotherapies may be more effective than monotherapies. In this review, the authors discuss emerging combinations of immunotherapies and compare efficacy of single vs. combined therapies tested in preclinical brain tumor models. Expert opinion: Malignant gliomas are characterized by a number of factors which may limit the success of single immunotherapies including inter-tumor and intra-tumor heterogeneity, intrinsic resistance to traditional therapies, immunosuppression, and immune selection for tumor cells with low antigenicity. Combination of therapies which target multiple aspects of tumor physiology are likely to be more effective than single therapies. While a limited number of combination immunotherapies are described which are currently being tested in preclinical and clinical studies, the field is expanding at an astounding rate, and endless combinations remain open for exploration.
Palabras clave:
Cancer Vaccines
,
Gene Therapy
,
Glioma
,
Immune Checkpoint Blockade
,
Immunotherapy
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(BIOMED)
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Articulos(INBIOMED)
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS
Citación
Chandran, Mayuri; Candolfi, Marianela; Shah, Diana; Mineharu, Yohei; Yadav, Viveka Nand; et al.; Single vs. combination immunotherapeutic strategies for glioma; Informa Healthcare; Expert Opinion on Biological Therapy; 17; 5; 5-2017; 543-554
Compartir
Altmétricas